Small Molecule drug treatment is one of the main approaches in treating cancer. Until recent years, chemotherapy was the only...

109 Antibody Drug Conjugates Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.

90 Antibody Drug Conjugates Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.

90 Bi-specific Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.

109 Bi-specific Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.

Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.

Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.  

In 1986, muromonab-CD3 (OKT3) wins the first therapeutic monoclonal antibody approval from the US FDA, which works as an immunosuppressive...

Small- molecule kinase inhibitors have the potential for broad efficacy, convenience and tissue penetrance, and thus often offer important advantages...

First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...